Abstract: Prostate cancer (PC) is a leading cause of cancer-related morbidity and mortality in men, with metastatic castration-resistant prostate cancer (mCRPC) representing a highly aggressive and lethal disease state. Genomic profiling has revealed that up to 30% of mCRPC patients harbor mutations in homologous recombination repair (HRR) genes, most notably BRCA1, BRCA2, and ATM. Olaparib (AZD2281) is a potent, orally bioavailable poly (ADP-ribose) polymerase (PARP) inhibitor that exploits these genetic vulnerabilities through a mechanism known as synthetic lethality. By inhibiting PARP enzymes and trapping them on damaged DNA, olaparib induces selective cytotoxicity in HRR-deficient tumor cells. Landmark clinical trials, including TOPARP, PROfound, and PROpel, have demonstrated the significant clinical efficacy of olaparib in improving radiographic progression-free survival (rPFS) and overall survival (OS) in mCRPC patients, leading to its FDA approval. Despite its success, the clinical utility of olaparib is limited by hematological toxicities, the emergence of drug resistance, and the financial burden of treatment and requisite genetic testing. Ongoing research is focused on expanding olaparib's role through combination therapies—such as with androgen receptor pathway inhibitors (ARPIs), immunotherapy, and radioligand therapy—and exploring its efficacy in earlier stages of prostate cancer.
1. Introduction
Prostate cancer (PC) is one of the most frequently diagnosed malignancies worldwide and a leading cause of cancer-related deaths in men [1]. While localized disease can often be managed effectively, a significant proportion of patients progress to metastatic castration-resistant prostate cancer (mCRPC), an incurable and fatal disease state that no longer responds to first-line androgen deprivation therapy (ADT) [2]. In recent years, genomic sequencing has revolutionized the therapeutic landscape of mCRPC by identifying actionable molecular targets. It is estimated that approximately 20% to 30% of mCRPC patients possess germline or somatic mutations in homologous recombination repair (HRR) genes, with BRCA1, BRCA2, and ATM being the most prevalent [1][2].
Olaparib (AZD2281) is a pioneering poly (ADP-ribose) polymerase (PARP) inhibitor designed to target these specific DNA repair defects. Based on compelling data from phase II and III clinical trials demonstrating improved survival outcomes, olaparib was granted breakthrough therapy designation and subsequently approved by the US Food and Drug Administration (FDA) in May 2020 for the treatment of mCRPC patients with deleterious or suspected deleterious HRR gene mutations who have progressed on prior novel hormonal agents [2]. This review synthesizes the pharmacological profile, molecular mechanisms, structural attributes, limitations, and future perspectives of olaparib in the management of advanced prostate cancer.
2. Pharmacological Activity
Olaparib is formulated for oral administration and exhibits a favorable pharmacokinetic profile. Following oral intake, the drug is rapidly absorbed, achieving peak plasma concentrations (Cmax) typically within 1 to 3 hours [1]. It has a mean apparent volume of distribution of 40.3 L and a mean apparent plasma clearance of 4.55 L/h [1]. The terminal half-life of olaparib is reported to be between 6.10 and 11.9 hours [1][4]. The drug is primarily metabolized in the liver by the cytochrome P450 isozyme 3A (CYP3A4), and its metabolites are eliminated through both urine (35%–50%) and feces (12%–60%) [1].
The clinical pharmacological activity of olaparib in mCRPC has been established through several landmark trials. The phase II TOPARP-A trial evaluated olaparib (400 mg twice daily) in heavily pretreated mCRPC patients, revealing an overall response rate of 33%. Strikingly, patients with HRR gene aberrations exhibited an 88% response rate, including a 100% response rate in patients with BRCA2 loss [1][2]. The subsequent phase III PROfound trial confirmed these findings, demonstrating that olaparib significantly prolonged median radiographic progression-free survival (rPFS) (7.4 vs. 3.6 months) and overall survival (OS) (19.1 vs. 14.7 months) compared to enzalutamide or abiraterone in patients with BRCA1, BRCA2, or ATM mutations [2][3]. More recently, the phase III PROpel trial investigated olaparib in combination with abiraterone as a first-line therapy for mCRPC, showing a significant improvement in rPFS and OS in a biomarker-unselected population, though the greatest benefit remained in the BRCA-mutated subgroup [3][8].
3. Molecular Mechanism of Action
The primary mechanism of action of olaparib is rooted in the genetic concept of "synthetic lethality." Normal cells rely on multiple pathways to repair DNA damage, including base-excision repair for single-strand breaks (SSBs) and homologous recombination (HR) for double-strand breaks (DSBs) [1]. PARP1 and PARP2 are nuclear enzymes critical for detecting and repairing SSBs. When olaparib inhibits PARP activity, SSBs accumulate and degenerate into highly toxic DSBs during DNA replication [3][4].
In healthy cells, these DSBs are accurately repaired by the HR pathway. However, in prostate cancer cells harboring deleterious mutations in HRR genes (such as BRCA1 or BRCA2), the HR pathway is defective. Consequently, the cells are forced to rely on error-prone repair mechanisms like non-homologous end-joining, leading to massive genomic instability and selective tumor cell apoptosis [1][4]. Furthermore, olaparib exerts cytotoxicity by "trapping" PARP enzymes at the site of DNA damage. These trapped PARP-DNA complexes physically obstruct replication forks, proving to be significantly more cytotoxic than the unrepaired SSBs caused by catalytic PARP inhibition alone [3][4].
Additionally, preclinical evidence suggests a mechanistic crosstalk between the androgen receptor (AR) pathway and DNA repair. AR signaling regulates the expression of DNA repair genes; thus, AR pathway inhibitors (ARPIs) can induce a state of HRR deficiency (a "BRCAness" phenotype), providing a strong biological rationale for the synergistic combination of olaparib with agents like abiraterone or enzalutamide [3][9].
4. Structure-Activity Relationship (SAR)
While all clinically approved PARP inhibitors share the ability to competitively bind to the NAD+ binding pocket of the PARP catalytic domain, their structural differences dictate their varying capacities for "PARP trapping"—the ability to lock the PARP enzyme onto the DNA strand. The structure-activity relationship of these compounds is clinically categorized by their trapping potency [4].
Among the FDA-approved PARP inhibitors, trapping potency varies significantly. On a scale of 1 to 5 (where 1 is the most potent), talazoparib ranks as the most potent trapper (score of 1), being approximately 100-fold more potent at trapping PARP-DNA complexes than olaparib. Niraparib follows with a score of 2, rucaparib with a score of 3, olaparib with a score of 4, and veliparib is the weakest trapper with a score of 5 [4]. Olaparib's specific structural conformation allows for effective catalytic inhibition and moderate PARP trapping, striking a balance that provides robust synthetic lethality in BRCA-deficient cells while maintaining a manageable safety profile compared to the highly potent but potentially more toxic talazoparib [4].
5. Current Limitations
Despite its transformative impact, the clinical application of olaparib is hindered by several limitations:
Toxicity and Adverse Events: Olaparib is associated with significant hematological toxicities. Meta-analyses of phase II and III trials indicate that PARP inhibitors significantly increase the risk of all-grade and high-grade anemia, thrombocytopenia, and neutropenia [5]. Anemia is the most common severe adverse event, often requiring dose interruptions, reductions, or blood transfusions [3][5]. Gastrointestinal side effects (nausea, vomiting, decreased appetite) and fatigue are also highly prevalent [1]. Furthermore, there is a rare but severe risk of developing secondary malignancies, such as myelodysplastic syndrome and acute myeloid leukemia [1][4].
Drug Resistance and Variable Efficacy: Not all HRR mutations confer the same sensitivity to olaparib. For instance, while BRCA1/2 mutations show profound responses, patients with ATM mutations derive a weaker benefit. In ATM-deficient cancer cells, PARP inhibition alone has been shown to be cytostatic rather than cytotoxic, often requiring the addition of an ATR inhibitor to induce cell death [6]. Additionally, prolonged exposure to olaparib can lead to acquired resistance through secondary reversion mutations in BRCA genes or the rewiring of the tumor microenvironment and DDR pathways [10].
Financial and Logistical Barriers: The financial toxicity of olaparib is substantial, with estimated costs around $12,000 per month, significantly higher than standard chemotherapies like docetaxel [2]. Furthermore, the necessity for somatic and/or germline genetic testing (via tumor tissue or circulating tumor DNA) to identify eligible patients adds logistical complexity and additional costs to the treatment paradigm [2][3].
6. Future Perspectives
The future of olaparib in prostate cancer lies in expanding its utility beyond monotherapy in late-stage disease. A major focus is the development of rational combination strategies to overcome resistance and extend benefits to HRR-proficient tumors. Ongoing clinical trials are evaluating olaparib in combination with immune checkpoint inhibitors (e.g., pembrolizumab in the Keynote-365 trial, or durvalumab), ATR inhibitors (e.g., AZD6738), and VEGF inhibitors (e.g., cediranib) [1][7]. Additionally, combining olaparib with targeted radioligand therapies, such as 177Lu-PSMA-617, represents a highly promising frontier for synergistic cytotoxicity [2][7].
Researchers are also investigating the efficacy of olaparib in earlier stages of prostate cancer. Trials are currently assessing its feasibility as a neoadjuvant treatment prior to radical prostatectomy in patients with high-risk localized disease [1]. As molecular profiling becomes more integrated into routine clinical practice, the refinement of biomarkers beyond BRCA1/2 will be crucial for optimizing patient selection, sequencing therapies effectively, and fully realizing the potential of precision oncology in prostate cancer [8][10].
